Home > Insider Trading > Filing (0001179110-20-008770)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1235010	Momenta Pharmaceuticals Inc	MNTA	Biological Products, (No Disgnostic Substances) (2836)	043561634

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1706857	Santiago Arroyo	C/O Momenta Pharmaceuticals, Inc. 301 Binney Street Cambridge MA 02142	Svp, Chief Medical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2020-08-04	10,156	$12.76	12,136	No	4	M	Direct
Common Stock	Acquisiton	2020-08-04	22,500	$17.20	34,636	No	4	M	Direct
Common Stock	Disposition	2020-08-04	34,542	$32.25	94	No	4	S	Direct
Common Stock	Disposition	2020-08-05	94	$32.65	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2020-08-04	10,156	$0.00	10,156	$12.76
Common Stock	Stock Option (Right to Buy)	Disposition	2020-08-04	22,500	$0.00	22,500	$17.20

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
73,702	2020-05-11	2029-02-11	No	4	M	Direct
36,748	2020-03-20	2027-06-20	No	4	M	Direct

Footnotes

This transaction was effected pursuant to a Rule 10b5-1 trading plan.
Includes 94 shares acquired under the issuer's employee stock purchase plan at a price of $24.98 per share on July 31, 2020
This transaction was executed in multiple trades at prices ranging from $31.34 to $32.90. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
This transaction was executed in multiple trades at prices ranging from $32.51 to $32.82. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.